Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Mallinckrodt
Medtronic
McKinsey

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Methylnaltrexone bromide - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for methylnaltrexone bromide and what is the scope of patent protection?

Methylnaltrexone bromide is the generic ingredient in one branded drug marketed by Salix Pharms and Salix, and is included in two NDAs. There are fourteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Methylnaltrexone bromide has one hundred and nineteen patent family members in thirty-seven countries.

There are three drug master file entries for methylnaltrexone bromide. One supplier is listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for methylnaltrexone bromide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Karolinska University HospitalPhase 4
University Medicine GreifswaldPhase 1
Valeant Pharmaceuticals International, Inc.Phase 1

See all methylnaltrexone bromide clinical trials

Recent Litigation for methylnaltrexone bromide

Identify potential future generic entrants

District Court Litigation
Case NameDate
BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC.2019-06-13
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LABORATORIES FL, INC.2017-12-08
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARAMACEUTICALS, INC.2017-09-01

See all methylnaltrexone bromide litigation

Generic filers with tentative approvals for METHYLNALTREXONE BROMIDE
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial12MG/0.6MLINJECTABLE;SUBCUTANEOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for methylnaltrexone bromide
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for methylnaltrexone bromide
(17R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6- oxomorphinanium bromide
(17R)-Methylnaltrexone bromide
(17RS)-17-(Cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-17-methyl-6- oxomorphinanium bromide
(17S)-N-Methylnaltrexone bromide
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one,bromide
(5|A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium Bromide
(R)-N-Methylnaltrexone bromide
(R)-Naltrexone methobromide
(R)-Naltrexone methylbromide
(S)-Naltrexone methobromide
1055877-28-5
1378943-67-9
3844AH
73232-52-7
916045-21-1
916055-92-0
AKOS015896214
AN-37324
BC276097
C21H26NO4.Br
CDW853B60I
CHEMBL1201770
CS-0762
D06618
HY-75766
I06-1616
IFGIYSGOEZJNBE-KNLJMPJLSA-N
Methylnaltrexone
Methylnaltrexone (Bromide)
Methylnaltrexone bromide (JAN/USAN)
Methylnaltrexone bromide [USAN:INN:BAN]
Methylnaltrexone bromide, (17S)-
Methylnaltrexone bromide, >=97% (HPLC)
Methylnaltrexone bromide, United States Pharmacopeia (USP) Reference Standard
MNTX
MNTX-302
MOA 728
MOA-728
Morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17S)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17- methyl-6-oxo-,bromide,(5alpha)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5alpha)-
Morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,9-dihydroxy-17-methyl-6-oxo-, bromide (1:1), (17S)-
MRZ 2663BR
MRZ-2663BR
N-Cyclopropylmethyl-noroxymorphone Methobromide
N-Methyl Naltrexone Bromide
N-Methylnaltrexone Bromide
Naltrexone (R)-methobromide
Naltrexone (S)-methobromide
Naltrexone methobromide
Naltrexone Methyl Bromide
ONO-3849
Relistor
Relistor (TN)
RFO6IL3D3M
SCHEMBL2798188
UNII-CDW853B60I
UNII-RFO6IL3D3M
UNII-RFO6IL3D3M component IFGIYSGOEZJNBE-LHJYHSJWSA-N
UNII-RFO6IL3D3M component IFGIYSGOEZJNBE-NQMNLMSRSA-N
W-5330
Paragraph IV (Patent) Challenges for METHYLNALTREXONE BROMIDE
Tradename Dosage Ingredient NDA Submissiondate
RELISTOR TABLET;ORAL methylnaltrexone bromide 208271 2016-09-06
RELISTOR SOLUTION;SUBCUTANEOUS methylnaltrexone bromide 021964 2015-09-08

US Patents and Regulatory Information for methylnaltrexone bromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for methylnaltrexone bromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016   Start Trial   Start Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010   Start Trial   Start Trial
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Mallinckrodt
Harvard Business School
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.